Consensus on precision medicine for metastatic cancers: a report from the MAP conference

C Swanton; J-C Soria; A Bardelli; A Biankin; C Caldas; S Chandarlapaty; L de Koning; C Dive; J Feunteun; S-Y Leung; R Marais; E R Mardis; N McGranahan; G Middleton; S A Quezada; J Rodón; N Rosenfeld; C Sotiriou; F André

doi:10.1093/annonc/mdw192

Consensus on precision medicine for metastatic cancers: a report from the MAP conference

Ann Oncol. 2016 Aug;27(8):1443-8. doi: 10.1093/annonc/mdw192. Epub 2016 May 3.

Authors

C Swanton¹, J-C Soria², A Bardelli³, A Biankin⁴, C Caldas⁵, S Chandarlapaty⁶, L de Koning⁷, C Dive⁸, J Feunteun⁹, S-Y Leung¹⁰, R Marais¹¹, E R Mardis¹², N McGranahan¹³, G Middleton¹⁴, S A Quezada¹⁵, J Rodón¹⁶, N Rosenfeld¹⁷, C Sotiriou¹⁸, F André¹⁹

Affiliations

¹ Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London UCL Hospitals and Cancer Institute, London, UK.
² Drug Development Unit, Gustave Roussy, Villejuif Department of Medical Oncology, INSERM Unit U981, Faculté de medicine Paris-Sud XI, Kremlin-Bicêtre, Villejuif, France.
³ Department of Oncology, University of Torino, Candiolo, Torino Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
⁴ Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, UK South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Liverpool, New South Wales, Australia West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow.
⁵ Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
⁶ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
⁷ Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
⁸ Clinical and Experimental Pharmacology, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
⁹ Stabilité Génétique et Oncogenèse, Université Paris-Sud, Gustave-Roussy, Villejuif, France.
¹⁰ Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
¹¹ Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
¹² McDonnell Genome Institute, Washington University School of Medicine, St Louis, USA.
¹³ Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London.
¹⁴ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham.
¹⁵ Cancer Immunology Unit, University College London Cancer Institute, University College London, London, UK.
¹⁶ Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
¹⁷ Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge.
¹⁸ Breast Cancer Translational Research Laboratory-BCTL (ULB 290), Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
¹⁹ Department of Medical Oncology, INSERM Unit U981, Faculté de medicine Paris-Sud XI, Kremlin-Bicêtre, Villejuif, France fandre@igr.fr fabrice.andre@igr.fr.

PMID: 27143638
DOI: 10.1093/annonc/mdw192

Abstract

Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered. There was a consensus that new technologies like next-generation sequencing of tumors and ddPCR on circulating free DNA have convincing analytical validity. Further work needs to be undertaken to establish the clinical utility of liquid biopsies and the added clinical value of expanding from individual gene tests into large gene panels. Experts agreed that standardized bioinformatics methods for biological interpretation of genomic data are needed and that precision medicine trials should be stratified based on the level of evidence available for the genomic alterations identified.

Keywords: biomarkers; consensus; precision medicine.

MeSH terms

Genomics
High-Throughput Nucleotide Sequencing
Humans
Molecular Targeted Therapy*
Neoplasms / drug therapy*
Neoplasms / genetics*
Neoplasms / pathology
Precision Medicine
Proteomics*

Abstract

MeSH terms

Grants and funding